GLP-1 Receptor Agonists Pose Emerging Eating Disorder Risks, Necessitating Coordinated Clinical and Research Agenda

The rapid adoption of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related incretin-based medications has revolutionized treatment for type 2 diabetes, obesity, and cardiovascular risk reduction. These drugs exert profound effects on appetite, satiety, and reward-related eating, directly impacting core psychological and behavioral domains relevant to eating disorders. A critical gap exists in understanding and mitigating the potential for these powerful metabolic agents to exacerbate or trigger eating disorder psychopathology in vulnerable populations, necessitating a proactive clinical and research framework.

This Spotlight article synthesizes emerging clinical concerns and early evidence regarding GLP-1 RA use in populations exhibiting various eating disorder symptoms, including binge eating, bulimic symptoms, restrictive eating, body image disturbance, and weight stigma exposure. The authors focused on identifying unresolved questions and critical gaps in current practice rather than conducting a systematic review. They drew upon existing literature and clinical observations to argue for an urgent, coordinated clinical and research agenda for the GLP-1 era.

While GLP-1 RAs show therapeutic promise for some individuals with binge eating disorder or loss-of-control eating, the very mechanisms that reduce appetite and food preoccupation can also inadvertently reinforce maladaptive behaviors. These include restriction, avoidance of regular eating, compulsive weight control, and relapse in vulnerable individuals. A significant finding is the current lack of systematic eating disorder screening within prescribing pathways, along with insufficient multidisciplinary monitoring and guidance. This gap makes it challenging to distinguish medically appropriate appetite modulation from emerging or worsening eating disorder psychopathology. The article highlights that current protocols often fail to integrate comprehensive assessment for body image disturbance or weight stigma exposure, which are critical factors in eating disorder development and exacerbation.

Current prescribing pathways often lack systematic eating disorder screening, multidisciplinary monitoring, and guidance on how to distinguish medically appropriate appetite modulation from emerging or worsening eating disorder psychopathology.